oncgnostics GmbH aus Jena auf der MEDICA 2019 in Düsseldorf -- COMPAMED Messe
Option auswählen

oncgnostics GmbH

Winzerlaer Str. 2, 07745 Jena

Dieser Aussteller ist Mitaussteller von
Thüringen c/o medways e.V.


MEDICA 2019 Hallenplan (Halle 15): Stand L29


MEDICA 2019 Geländeplan: Halle 15


Dr. Alfred Hansel




Besuchen Sie uns!

Halle 15 / L29



17:30 - 20:00


Wir laden Sie ganz herzlich ein zu unserem Thüringenabend am Dienstag ab 17.30 Uhr am Thüringer Gemeinschaftstand! Vertreter aus der Politik Thüringens werden uns an dem Abend besuchen. Außerdem wird es original Thüringer Bratwürste geben!!! 
Wir freuen uns auf einen interessanten Abend, kommen Sie gern vorbei!

Mehr Weniger

Unser Angebot


  • 03  Diagnostika
  • 03.06  Gentests, molekularbiologische Diagnostik
  • 03.06.01  DNA-Tests
  • 03  Diagnostika
  • 03.06  Gentests, molekularbiologische Diagnostik
  • 03.06.02  Molekulare Biomarker
  • 03  Diagnostika
  • 03.06  Gentests, molekularbiologische Diagnostik
  • 03.06.03  Polymerase chain reaction (PCR)
  • 03  Diagnostika
  • 03.06  Gentests, molekularbiologische Diagnostik
  • 03.06.04  Sonstige molekularbiologische Diagnostiktests

Unsere Produkte

Produktkategorie: Molekulare Biomarker, DNA-Tests, Polymerase chain reaction (PCR), Sonstige molekularbiologische Diagnostiktests

GynTect - reliable cervical cancer diagnostics

GynTect, an CE IVD labelled in-vitro diagnostic assay, is based on epigenetic biomarkers and is intended to be used in cervical cancer diagnostics. 
GynTect showes exceptional specificity compared to other tests like HPV test, p16/Ki67 or cytology by having 100% sensitivity at the same time for cancer cases.

Mehr Weniger

Produktkategorie: DNA-Tests, Molekulare Biomarker, Polymerase chain reaction (PCR), Sonstige molekularbiologische Diagnostiktests

Head and neck cancer detection

Based on epigenetic markers, we are developing in-vitro diagnostic assays a) for early detection and b) follow-up care of head and neck cancer.
Launch will be end of 2020.

Mehr Weniger

Produktkategorie: DNA-Tests, Molekulare Biomarker, Polymerase chain reaction (PCR), Sonstige molekularbiologische Diagnostiktests

Ovarian cancer detection

Based on epigenetic markers, we are developing in-vitro diagnostic assays for a) ovarian cancer screening and b) therapy decision after surgery. This development is a joint project with the University Women's Hospital in Jena, an CE IVD certified assay will be launched earliest in 2021.

Mehr Weniger






Early detection test GynTect® now available for Roche Diagnostics QPCR system

Jena, 20. February, 2019 – The test for early detection of cervical cancer GynTect® may now also be performed on the cobas Z480 analyzer, a widely used quantitative PCR (QPCR) system from Roche Diagnostics. This is now possible through an extension of the GynTect® CE IVD mark (CE mark for in vitro diagnostics). The biotech company oncgnostics GmbH is developer and provider of GynTect®.

GynTect® allows a fast and reliable clarification, if a patient with abnormal Pap smear findings or an HPV infection, is about to develop or already has cervical cancer. GynTect® allows to detect modified, esp. methylated DNA regions. Methylation of these DNA regions specifically occurs in cervical cancer.

Performance of GynTect using the Cobas Z480
Two steps are required for the performance of GynTect®. In the first step a chemical treatment with bisulphite fixates the DNA methylation of the diagnostic material. For the detection of the marker regions a PCR (Polymerase Chain Reaction) is required. The cobas Z480 Analyzer by Roche Diagnostics allows the performance of such a diagnostic PCR. Based on the data obtained in the PCR, the GynTect® results are derived. Only originally methylated DNA regions present in the sample are amplified during the PCR. This procedure is termed methylation-specific PCR (MSP).

More laboratories may perform GynTect® now
“By now GynTect® could only be performed on the ABI7500 Real-Time PCR system from Life Technologies. Extension of the CE IVD mark now allows to run the test on the cobas Z480 PCR system as well. With its widespread availability many more laboratories now can perform GynTect® without any additional expenses”, Alfred Hansel, co-founder and CEO of oncgnostics said.

Mehr Weniger

Über uns


We at oncgnostics are specialized in the development of in vitro diagnostic tests for all areas of cancer diagnostics.

Our tests are based on epigenetic changes, so called DNA methylations which are characteristic for cancer cells. These highly informative biomarkers, validated and patented by us, represent the core of our products and provide the basis for our activities.

Our business strategy aims in the IVD test development field at, after test validation and initial preclinical trials, cooperation with international partners. After registration, products will be marketed directly or through licensing to cooperation or distribution partners.

Mehr Weniger



< 1 Mio US $

Anzahl der Beschäftigten